haematology critical-care
SIC Score (Sepsis-Induced Coagulopathy)
Identifies sepsis-induced coagulopathy (SIC) as an early phase of DIC. Identifies patients who may benefit from anticoagulation.
Score interpretation
SIC Absent 0–3
Does not meet SIC criteria
→ Monitor; recheck coagulation if clinical deterioration
SIC Present 4–6
Meets SIC criteria — high risk of progression to overt DIC
→ Consider anticoagulation (LMWH/UFH per local protocol); treat underlying sepsis aggressively
Interpretation bands for the SIC Score. Apply clinical judgement and local guidance.
References
- Iba T et al. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24(1):360.
- Iba T et al. Revised scoring criteria for sepsis-induced coagulopathy (SIC). Thromb Res. 2019;176:125–127.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Bivalirudin (PCI Anticoagulation) · Direct Thrombin Inhibitor / PCI
- Prothrombin Complex Concentrate (PCC) · Coagulation Factor Concentrate — Warfarin Reversal
- Bivalirudin · Anticoagulation
- Phytomenadione (Vitamin K1) · Vitamin K (Coagulation Factor Synthesis)
- Factor IX Concentrate · Coagulation Factor Replacement — Haemophilia B
- Fibrinogen Concentrate · Coagulation Factor Replacement — Hypofibrinogenaemia
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.